Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Hepatocellular 19Neoplasm Metastasis 13Melanoma 12Nasopharyngeal Carcinoma 10Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 8Rectal Neoplasms 8Pancreatic Neoplasms 8Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Neoplasms 6Locally Advanced Rectal Cancer 6Carcinoma, Renal Cell 6Uterine Cervical Neoplasms 4Recurrence 4Lymphoma, Extranodal NK-T-Cell 4Triple Negative Breast Neoplasms 3Sarcoma 3Nasopharyngeal Neoplasms 3Glioblastoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Cholangiocarcinoma 3Thyroid Neoplasms 2Solid Tumor 2Prostatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Kidney Neoplasms 2Gastrointestinal Stromal Tumors 2

Interventions

Pemetrexed 9Drug Therapy 9osimertinib 7Radiotherapy 6Carboplatin 6anlotinib 5Radiosurgery 5aflutinib 4Gefitinib 4Docetaxel 4Cisplatin 4tislelizumab 3pembrolizumab 3icotinib 3Vinorelbine 3Paclitaxel 3Gemcitabine 3Erlotinib Hydrochloride 3toripalimab 2dacomitinib 2camrelizumab 2apatinib 2Tyrosine Kinase Inhibitors 2Thalidomide 2Surgical Procedures, Operative 2S 1 (combination) 2Platinum 2Liquid Biopsy 2Immune Checkpoint Inhibitors 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × NSCLC × spartalizumab × Clear all
NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

The First Affiliated Hospital of Zhengzhou University

Phase 2/3 Unknown
150 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡